

Sarah Meyer, MD MPH
Captain, United States Public Health Service

Immunization Services Division
National Center for Immunization and Respiratory Diseases
1600 Clifton Road NE, Atlanta GA, 30329
Email: vif6@cdc.gov

EDUCATION

- 2008 **Doctor of Medicine (MD)**
 Saint Louis University School of Medicine, St. Louis, MO
- 2008 **Master of Public Health (MPH)**
 Saint Louis University College for Public Health and Social Justice, St. Louis, MO
- 2004 **Honors B.A. French / Honors B.A. International Studies / Biology minor**

POSTGRADUATE TRAINING

- 2023 **Advanced Course in Vaccinology (ADVAC)**
 Annecy, France
- 2011 – 2013 **Epidemic Intelligence Service Officer**
 Centers for Disease Control and Prevention, Atlanta, GA
- 2008 – 2011 **Pediatrics Resident**, Leadership in Equity and Advocacy (LEAD) track
 Boston Children's Hospital (Harvard University), Boston Medical Center (Boston University), Boston, MA

LICENSURE AND CERTIFICATION

- 2011 – Present American Board of Pediatrics
- 2011 – Present Georgia Medical License
- 2008 – Present Basic Life Support (BLS) provider

PROFESSIONAL EXPERIENCE

- 06/2022 – Present** **Chief Medical Officer**
 Immunization Services Division
 National Center for Immunization and Respiratory Diseases
 Centers for Disease Control and Prevention, Atlanta, GA
- 09/2019 – 6/2022** **Senior Medical Officer**
 Office of the Director
 National Center for Immunization and Respiratory Diseases
 Centers for Disease Control and Prevention, Atlanta, GA
- 07/2013 – 09/2019** **Medical Officer**
 Meningitis and Vaccine Preventable Diseases Branch
 National Center for Immunization and Respiratory Diseases
 Centers for Disease Control and Prevention, Atlanta, GA

07/2011 – 06/2013

Epidemic Intelligence Service Officer (2011-2013)

Meningitis and Vaccine Preventable Diseases Branch
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention, Atlanta, GA

ACADEMIC APPOINTMENTS

- 2017 – 2020 **Instructor of Pediatrics**, Emory University School of Medicine
2008 – 2011 **Clinical Fellow in Pediatrics**, Harvard Medical School
2008 – 2011 **Teaching Fellow in Pediatrics**, Boston University School of Medicine

PUBLICATIONS

1. Jones JM, Fleming-Dutra KE, Prill MM, Roper LE, Brooks O, Sanchez PJ, Kotton CN, Mahon BE, **Meyer S**, Long SS, McMorrow ML. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. *MMWR Morb Mortal Wkly Rep* 2023;72:920–925.
2. Wallace M, Rosenblum HG, Moulia DL, Broder KR, Shimabukuro TS, Taylor CA, Havers FP, **Meyer SA**, Dooling K, Oliver SE, Hadler SC, Gargano JW. Benefit-Risk Assessment Framework to Inform Policy Decisions: A Summary of the Advisory Committee for Immunization Practices Use of Benefit-Risk Assessments During the First Year of COVID-19 Vaccine Administration in the United States. *Vaccine*.
3. Moulia DL, Wallace M, Roper LE, Godfrey M, Rosenblum HG, Link-Gelles R, Britton A, Daley MF, **Meyer S**, Fleming-Dutra KE, Oliver SE, Twentyman E. Interim Recommendations for Use of Bivalent mRNA COVID-19 Vaccines for Persons Aged ≥ 6 Months — United States, April 2023. *MMWR Morb Mortal Wkly Rep* 2023;72:657–662.
4. Silk BJ, Scobie HM, Duck WM, Palmer T, Ahmad FB, Binder AM, Cisewski JA, Kroop S, Soetebeier K, Park M, Kite-Powell A, Cool A, Connelly E, Dietz S, Kirby AE, Hartnett K, Johnston J, Khan D, Stokley S, Paden CR, Sheppard M, Sutton P, Razzaghi H, Anderson RN, Thornburg N, **Meyer S**, Womack C, Weakland AP, McMorrow M, Broeker LR, Winn A, Hall AJ, Jackson B, Mahon BE, Ritchey MD. COVID-19 Surveillance after the Expiration of the Public Health Emergency Declaration—United States, May 11, 2023. *MMWR Morb Mortal Wkly Rep*. ePub: 5 May 2023.
5. Rosenblum HG, Wallace M, Roper LE, Godfrey M, Hall E, Fleming-Dutra KE, Link-Gelles R, Pilishvili T, Williams J, Moulia DL, Brooks O, Talbot HK, Lee GM, Bell BP, Daley M, **Meyer S**, Oliver SE, Twentyman E. Interim Recommendations from the Advisory Committee on Immunization Practices for the use of Bivalent Booster Doses of COVID-19 Vaccines — United States, 2022. *MMWR Morb Mortal Wkly Report* 2022; 71:1436-1441.
6. Twentyman E, Wallace M, Roper LE, Anderson TC, Rubis AB, Fleming-Dutra KE, Hall E, Hsu J, Rosenblum HG, Godfrey M, Archer WR, Moulia DL, Daniel L, Brooks O, Talbot HK, Lee GM, Bell BP, Daley M, **Meyer S**, Oliver S. Interim Recommendations of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥ 18 years – United States, July 2022. *MMWR Morb Mortal Wkly Rep* 2022;71:988-992.
7. Fleming-Dutra KE, Wallace M, Moulia DL, Twentyman E, Roper LE, Hall E, Link-Gelles R, Godfrey M, Woodworth KR, Anderson TC, Rubis AB, Shanley E, Jones JM, Morgan RL, Brooks O, Talbot HK, Lee GM, Bell BP, Daley M, **Meyer S**, Oliver S. Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months – 5 Years, United States, June 2022. *MMWR Morb Mortal Wkly Rep* 2022; 71:859-868.

8. Abara WE, Bernstein KT, Lewis FMT, Schillinger JA, Feemster K, Hariri S, Islam A, Eberhart M, Cheng I, Ternier A, Pathela P, Slutsker JS, **Mbaeyi S**, Madera R, Kirkcaldy RD. Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhea: a retrospective observational study. *Lancet Infectious Diseases*. 2022 Jul;22(7):1021-1029.
9. Wallace M, Moulia D, Blain AE, Ricketts EK, Minhaj FS, Link-Gelles R, Curran KG, Hadler SC, Asif A, Godfrey M, Hall E, Fiore A, **Meyer S**, Su JR, Weintraub E, Oster ME, Shimabukuro TT, Campos-Outcalt D, Morgan RL, Bell BP, Brooks O, Talbot HK, Lee GM, Daley MF, Oliver SE. The Advisory Committee on Immunization Practices' Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥ 18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines – United States, February 2022. *MMWR Morb Mortal Wkly Rep* 2022; 71:416-421.
10. Whaley MJ, Vuong JT, Topaz N, Chang H, Thomas JD, Jenkins LT, Fang H, Schmink S, Steward-Clark E, Mathis M, Rodriguez-Rivera LD, Retchless AC, Joseph SJ, Chen A, Acosta, McNamara L, Soeters HM, **Mbaeyi S**, Wang X. Genetic variation underlying capsule expression in meningococcal carriage isolates from university students, 2015-2016. *Frontiers in Microbiology*. 2022.
11. Oliver SE, Wallace M, See I, **Mbaeyi S**, Godfrey M, Hadler SC, Jatlaoui TC, Twentyman E, Hughes MM, Rao AK, Fiore A, Su JR, Broder KR, Shimabukuro T, Lale A, Shay DK, Markowitz LE, Wharton M, Bell BP, Brooks O, McNally V, Lee GM, Talbot HK, Daley ME. Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices — United States, December 2021. *MMWR Morb Mortal Wkly Rep* 2022;71:90–95.
12. **Mbaeyi S**, McNamara L. Control of Serogroup W Meningococcal Disease Outbreaks: the Promise of Adolescent Vaccination. *Lancet Child & Adolescent Health*. December 2021.
13. Blain AE, Reese HE, Marjuki H, Topaz N, **Mbaeyi S**, McNamara LA. Serogroup A, C, W, and Y meningococcal disease in persons previously vaccinated with a serogroup ACWY meningococcal vaccine – United States, 2014-2018. *Vaccine*. November 2021.
14. Reese HE, McNamara LA, Vianzon V, Blain A, Topaz N, Many P, Barbeau B, Albertson JP, Lam E, DeBolt C, Zaremski EF, Hannagan SE, Evans D, Hariri S, Wang X, Granoff DM, **Mbaeyi S**. Serogroup B meningococcal disease in persons previously vaccinated with a serogroup B meningococcal vaccine – United States, 2014-2019. *Vaccine*. November 2021.
15. Woodworth KR, Moulia D, Collins JP, Hadler SC, Jones JM, Reddy SC, Chamberland M, Campos-Outcalt D, Morgan RL, Brooks O, Talbot HK, Lee GM, Bell BP, Daley MF, **Mbaeyi S**, Dooling K, Oliver SE. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021. *MMWR Morb Mortal Wkly Rep* 2021;70:1579–1583.
16. **Mbaeyi S**, Oliver SE, Collins JP, et al. The Advisory Committee on Immunization Practices' Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021. *MMWR Morb Mortal Wkly Rep* 2021;70:1545–1552.
17. Rosenblum HG, Hadler SC, Moulia D, Shimabukuro TT, Su JR, Tepper NK, Ess KC, Woo EJ, Mba-Jones A, Alimchandani M, Nair N, Klein NP, Hanson KE, Markowitz LE, Wharton M, McNally VV, Romero JR, Talbot K, Lee GM, Daley MF, **Mbaeyi SA**, Oliver SE. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021. *MMWR Morb Mortal Wkly Rep*. ePub: 10 August 2021.

18. Marjuki H, Chang H, Topaz N, Whaley M, Vuong J, Chen A, Jenkins LT, Fang H, Schmink S, Retchless AC, Thomas JD, Acosta A, McNamara L, Soeters HM, **Mbaeyi S**, Wang X. Genetic diversity of meningococcal serogroup B vaccine antigens among carriage isolates collected from three universities in the United States, 2015–2016. *mBio*. 2021.
19. Christie A, **Mbaeyi SA**, Walensky RP. CDC Interim Recommendations for Fully Vaccinated People: An Important First Step. *JAMA*. 2021.
20. Oliver SE, Gargano JW, Scobie H, Wallace M, Hadler SC, Leung J, Blain AE, McClung N, Campos-Outcalt D, Morgan RL, **Mbaeyi S**, MacNeil J, Romero J, Talbot HK, Lee G, Bell B, Dooling K. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021. *MMWR Morb Mortal Wkly Rep* 2021;70:329–332.
21. Fisher A, **Mbaeyi S**, Cohn A. Addressing vaccine hesitancy in the age of COVID-19. *Academic Pediatrics*. 2020.
22. McNamara L, **Mbaeyi S**. First immunogenicity data for the UK serogroup B meningococcal vaccination schedule in infants. *Lancet Infectious Diseases*. 2020.
23. Oliver S, Gargano J, Marin M, Wallace M, Curran K, Chamberland M, McClung N, Campos-Outcalt C, Morgan R, **Mbaeyi S**, Romero J, Talbot HK, Lee G, Bell B, Dooling K. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020. *MMWR Morb Mortal Wkly Rep*. ePub: 20 December 2020.
24. Oliver S, Gargano J, Marin M, Wallace M, Curran K, Chamberland M, McClung N, Campos-Outcalt C, Morgan R, **Mbaeyi S**, Romero J, Talbot HK, Lee G, Bell B, Dooling K. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020. *MMWR Morb Mortal Wkly Rep*. ePub: 20 December 2020.
25. **Mbaeyi S**, Fisher A, Cohn A. Strengthening vaccine confidence and acceptance in the pediatric provider office. *Pediatric Annals*. 2020. 49(12), e523-e531.
26. Topaz N, Kristiansen PA, Schmink S, Congo-Ouédraogo M, Kambiré D, **Mbaeyi S**, Paye M, Sangaré L, Ouédraogo R, Wang X. Whole genome analysis of meningococcal carriage isolates from Burkina Faso, 2016–2017. *Microbial Genomics* (2020): mgen000486.
27. **Mbaeyi S**, Bozio C, Duffy J, Rubin LG, Hariri S, Stephens DS, MacNeil JR. Meningococcal vaccination: Recommendations of the Advisory Committee on Immunization Practices. *MMWR*. September 2020. 69(9).
28. **Mbaeyi S**, Pondo T, Blain A, Yankey D, Potts C, Cohn A, Hariri S, Shang N, MacNeil JR. Meningococcal disease incidence before and after implementation of quadrivalent meningococcal conjugate vaccine in the United States. *JAMA Pediatrics*. 2020. 174(9), 843-851.
29. **Mbaeyi S**, Sampo E, Dinanibè K, Yaméogo I, Congo-Ouédraogo M, Tamboura M, Sawadogo G, Ouattara K, Sanou M, Kiemtoré T, Dioma G, Sanon B, Somlare H, Kyetega A, Ba A, Aké F, Tarbangdo F, Aboua F, Donnou Y, Kamaté I, Adnan S, Patel J, Schmink S, Spiller MW, Topaz N, Novak R, Wang X, Bicaba B, Sangaré L, Ouédraogo-Traoré, Kristiansen PA. Meningococcal carriage seven years after introduction of a serogroup A meningococcal conjugate vaccine in Burkina Faso: results from cross-sectional carriage surveys. *Lancet Infectious Diseases*. 2020. 20(12), 1418-1425.

30. **Mbaeyi S**, Cohn A, Messonnier N. A call to action: strengthening vaccine confidence in the United States. *Pediatrics*. June 2020. 145(6):e20200390.
31. Joseph S, Topaz N, Chang H, Whaley M, Vuong JT, Chen A, Hu F, Schmink S, Jenkins LT, Rodriguez-Rivera L, Thomas JD, Acosta A, McNamara L, Soeters HM, **Mbaeyi S**, Wang X. Insights on population structure and within-host genetic changes among meningococcal carriage isolates from U.S universities. *mSphere*. 2020 Apr 8;5(2). pii: e00197-20.
32. Bajema KL, Oster AM, McGovern OL, Lindstrom S, Stenger MR, Anderson TC, Isenhour C, Clarke KR, Evans ME, Chu VT, Biggs HM, Kirking HL, Gerber SI, Hall AJ, Fry AM, Oliver SE, **2019-nCoV Persons Under Investigation Team (includes Mbaeyi S)**. Persons Evaluated for 2019 Novel Coronavirus – United States, January 2020. *MMWR Morb Mortal Wkly Rep*. ePub: 7 February 2020.
33. Oliver SE, Patton ME, Hoban M, Leino V, **Mbaeyi S**, Hariri S, MacNeil J. Evaluation of meningococcal vaccination policies among colleges and universities – United States, 2017. *Journal of American College Health*. 2019. DOI:10.1080/07448481.2019.1687484.
34. **Mbaeyi SA**, Lingani C, Diallo AO, Bicaba B, Ouedraogo R, Acyl M, Gamougane K, Coulibaly O, Coulibaly S, Zaneidou M, Sidikou F, Nikiema C, Sadji AY, Ake F, Tarbangdo F, Sakande S, Tall H, Njanpop-Lafourcade BM, Moisi J, N'Diaye A, Bwaka A, Bita A, Fernandez K, Poy A, Soeters HM, Vuong J, Novak R, Ronveaux O for the MenAfriNet consortium. Improving case-based meningitis surveillance in 5 countries in the meningitis belt of sub-Saharan Africa, 2015–2017. *Journal of Infectious Diseases*. 2019; 220(S_4):S155-164.
35. Sidikou F, Potts CC, Zaneidou M, **Mbaeyi S**, Kadadé G, Paye MF, Ousmane S, Issaka B, Chen A, Chang HY, Issifou D, Bienvenu B, Mahame AE, Diallo AO, Moussa A, Seidou I, Abdou M, Sidiki A, Garba O, Haladou S, Testa J, Pana A, Obama R, Mainassara H, Wang X. Epidemiology of Bacterial Meningitis in the Nine Years Since Meningococcal Serogroup A Conjugate Vaccine Introduction, Niger, 2010–2018. *Journal of Infectious Diseases*. 2019; 220(S_4):S206-215.
36. Soeters HM, Diallo AO, Bicaba BW, Kadadé G, Dembélé A, Acyl M, Nikima C, Sadji AY, Poy AN, Lingani C, Tall H, Sakande S, Tarbangdo F, Aké F, **Mbaeyi SA**, Moisi J, Paye MF, Sanogo YO, Vuong JT, Wang X, Ronveaux O, Novak RT for the MenAfriNet consortium. Bacterial meningitis epidemiology in 5 countries in the meningitis belt of sub-Saharan Africa, 2015–2017. *Journal of Infectious Diseases*. 2019; 220(S_4):S165-S174.
37. Patel JC, Soeters HM, Diallo AO, Bicaba BW, Kadadé G, Maiga M, Acyl M, Tamekloe TA, Lingani C, Hatcher C, Thomas J, Mihigo R, Hajjeh R, Zilber C, Aké F, **Mbaeyi SA**, Wang X, Moisi J, Ronveaux O, Mwenda J, Novak RT for the MenAfriNet consortium. MenAfriNet: a network supporting case-based meningitis surveillance and vaccine evaluation in the meningitis belt of Africa. *Journal of Infectious Diseases*. 2019; 220(S_4):S148-154.
38. **Mbaeyi S**, Stokley S. Meningococcal conjugate vaccine in the United States: Remaining challenges for adolescent vaccination. *Journal of Adolescent Health*. 2019. 65(1):11-12.
39. Peterson ME, Li Y, Shanks H, Mile R, Nair H, Kyaw MH, Amicizia D, Bayliss CD, Carvalho Campos L, Cleary PR, Delbos V, Esposito S, Kristiansen PA, **Mbaeyi SA**, Oldfield NJ, Panatto D, Rodrigues F, Turner DPJ, Xu A. Serogroup-specific meningococcal carriage by age group: a systematic review and meta-analysis. *BMJ Open*. 2019; 9(4):e024343.

40. Soeters HM, McNamara LA, Blain AE, Whaley M, MacNeil JR, Hariri S, **Mbaeyi SA**. University-based serogroup B meningococcal disease outbreaks, United States, 2013-108. Emerging Infectious Diseases. 2019. Emerging Infectious Diseases 25(3):434-440.
41. **Mbaeyi SA**, Joseph S, Blain A, Wang X, Hariri S, MacNeil J. Meningococcal disease among college-aged young adults – United States, 2014-2016. Pediatrics. December 2018. DOI: 10.1542/peds.2008-1536
42. Whaley M, Joseph S, Retchless A, Kretz C, Blain A, Hu F, Chang H, **Mbaeyi SA**, MacNeil J, Read T, Wang X. Whole genome sequencing for investigations of meningococcal outbreaks in the United States: a retrospective analysis. Scientific Reports. 2018. 8(1):1-13.
43. Jackson M, Diallo AO, Medah I, Bicaba B, Yameogo I, Koussoube D, Ouedraogo R, Sangare L, **Mbaeyi SA**. Initiation validation of a simulation model for estimating the impact of serogroup A *Neisseria meningitidis* vaccination in the African meningitis belt. PLOS ONE. 2018. 13(10):1-15.
44. **Mbaeyi SA**, Faulkner A, Miner C, Edge K, Cruz V, Pena S, Kudish K, Coleman J, Pradhan E, Thomas S, Martin S, Skoff T. Severe Pertussis Infections in the United States, 2011-2015. Clinical Infectious Diseases. October 2018: <https://doi.org/10.1093/cid/ciy889>
45. Oliver S, **Mbaeyi SA**. A review of global epidemiology and response to meningococcal disease outbreaks among men who have sex with men, 2001-2018. Current epidemiology reports. September 2018. DOI: 10.1007/s40471-018-0170-z.
46. **Mbaeyi SA**, Blain A, Whaley MJ, Wang X, Cohn AC, MacNeil JR. Epidemiology of meningococcal disease outbreaks in the United States, 2009-2013. Clinical Infectious Diseases. 2018. DOI: 10.1093/cid/ciy548
47. Bozio CH, Blain A, MacNeil J, Retchless A, Weil LM, Wang X, Jenkins LT, Rodriguez-Rivera L, Jarashow C, Ngo VP, Hariri S, **Mbaeyi SA**, Oliver S. Meningococcal Disease Surveillance in Men Who Have Sex with Men – United States, 2015-2016. MMWR. 67(38):1060-1063. September 2018.
48. Walker TJ, Elam-Evans L, Yankey D, Markowitz LE, Williams CL, **Mbaeyi SA**, Fredua B, Stokely S. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years – United States, 2017. MMWR. 67(33):909-917. August 2018.
49. O'Halloran AC, Lu PJ, **Meyer SA**, Williams W, Schumacher P, Sussell A, Birdsey J, Boal W, Sweeney M, Luckhaupt S, Black C, Santibanez T. Tdap vaccination among healthcare personnel – 21 states, 2013. American Journal of Preventive Medicine. 2018. 54(1): 119-123.
50. Breakwell L, Whaley M, Khan UI, Bandy U, Alexander-Scott N, Dupont L, Vanner C, Chang H, Vuong JT, Martin S, MacNeil JR, Wang X, **Meyer SA**. Meningococcal carriage among a university population – United States, 2015. Vaccine. 2017. 36(1): 29-35.
51. **Meyer SA**, Novak RT. Effect of a vaccine to prevent serogroup A *N. meningitidis* epidemics in Africa. The Lancet Infectious Diseases. 2017. 17(8):789-790.
52. Folaranmi TA, Kretz CB, Kamiya H, MacNeil JR, Whaley MJ, Blain A, Antwi M, Dorsenville M, Pacilli M, Smith S, Civen R, Ngo VP, Winter K, Harriman K, Wang X, Bowen V, Patel M, Martin SW, Misegades L, **Meyer SA**. Increased risk for meningococcal disease among men who have sex with men in the United States, 2012-2015. Clinical Infectious Diseases. 2017; 65(5):756-763.

53. Lu P, Yankey D, Jeyarajah J, O'Halloran A, **Meyer SA**, Elam-Evans L, Reagan-Steiner S. Impact of provider recommendations on Tdap vaccination of adolescents aged 13-17 years. *American Journal of Preventive Medicine*. 2017; 53(3):373-384.
54. Walker TJ, Elam-Evans L, Singleton JA, Yankey D, Markowitz L, Fredua B, Williams CL, **Meyer S**, Stokley S. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years – United States, 2016. *MMWR*. 66(33):874-882. August 2017.
55. **Meyer SA**, Kristiansen PA. Household transmission of *Neisseria meningitidis* in the meningitis belt. *The Lancet Global Health*. 2016; 4(12):e885-e886.
56. Kretz C, Retchless AC, Sidikou F, Issaka B, Ousmane S, Schwartz SB, Tate AH, Pana A, Njanpop-Lafourcade B, Nzeyimana I, Obama R, Deghmane A, Hong A, Brynildsrud O, Novak RT, **Meyer SA**, Ouwe Missi Oukem-Boyer O, Ronveaux O, Caugant DA, Taha MK, Wang X. Whole-genome characterization of epidemic *Neisseria meningitidis* serogroup C and resurging serogroup W, Niger, 2015. *Emerging Infectious Diseases*. 2016; 22(10):1762-1768.
57. Sidikou F, Zaneidou M, Alkassoum I, Schwartz SB, Issaka B, Obama R, Lingani C, Tate A, Ake F, Sakande S, Ousmane S, Zanguina J, Seidou I, Nzeyimana I, Moukoro D, Abodji O, Wang X, Taha MK, Moulia-Pelat JP, Pana A, Kadade G, Ronveaux O, Novak R, Ouwe Missi Oukem-Boyer O, **Meyer SA**. Emergence of epidemic *Neisseria meningitidis* serogroup C in Niger, 2015: An analysis of national surveillance data. *The Lancet Infectious Diseases*. 2016; 16(11): 1288-1294.
58. O'Halloran A, Lu P, Williams WW, Ding H, **Meyer SA**. Tetanus, diphtheria, and acellular pertussis vaccination among women of childbearing age – United States, 2013. *American Journal of Infection Control*. 2016; 44(2016): 786-93.
59. Nanduri S, Foo C, Ngo VP, Jarashow C, Civen R, Schwartz B, Holguin J, Shearer E, Zahn M, Harriman K, Winter K, Kretz C, Chang H, **Meyer SA**, MacNeil J. Outbreak of serogroup C meningococcal disease primarily affecting men who have sex with men (MSM) – Southern California, 2016. *MMWR*. 2016; 65(35): 939-940.
60. Rondy M, Issifou D, Alkassoum IS, Zaneidou M, Kadade G, Hamidou O, Sidikou F, Kissling E, **Meyer S**, Ronveaux O. Vaccine Effectiveness of Polysaccharide Vaccines Against Clinical Meningitis – Niamey, Niger, June 2015. *PLoS Currents*. 2016 Apr 18. Edition 1.
61. Mukhopadhyay S, **Meyer S**, Permar S, Puopolo KM. Symptomatic Postnatal Cytomegalovirus Testing among Very Low Birth Weight Infants: Indications and Outcomes. *American Journal of Perinatology*. 2016; 33(09): 894-902.
62. **Meyer SA**, Kambou JL, Cohn AC, et al. Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso – Implications for introduction of PsA-TT into the Expanded Programme on Immunization. *Vaccine*. 2015; 33(12): 1492-1498.
63. Alleman M, **Meyer SA**, Mulumba M, et al. Improved Acute Flaccid Paralysis Surveillance Performance in the Democratic Republic of the Congo, 2010-2012. *Journal of Infectious Diseases*. 2014; 210(S1): S50-61.
64. Bowden KE, Williams M, Cassiday P, Milton A, Pawloski L, Harrison M, Martin SW, **Meyer SA**, Qin X, Debolt C, Tasslimi A, Syed N, Sorrell R, Tran M, Hiatt B. Molecular Epidemiology of Pertussis Epidemic – Washington State, 2012. *Journal of Clinical Microbiology*. 2014; 52(10):3549-3557.

65. Meyer SA, Westreich DJ, Patel E, Ehlinger EP, Kalilani L, Lovingood RV, Denny TN, Swamy G, Permar SR. Postnatal cytomegalovirus exposure in infants of antiretroviral-treated and untreated HIV-infected mothers. *Infectious Diseases in Obstetrics and Gynecology*. 2014; 2014:1-8.
66. CDC (lead author). Serogroup A Conjugate Meningococcal Vaccine (PsA-TT) Coverage Following First National Mass Immunization Campaign – Burkina Faso, 2011. MMWR. Atlanta: US Department of Health and Human Services, CDC; 2012; 61(50); 1022-1024.
67. CDC (lead author). Pertussis Epidemic—Washington, 2012. MMWR. Atlanta: US Department of Health and Human Services, CDC; 2012; 61(28); 517-522.
68. Cama VA, Pearson J, Cabrera L, Pacheco L, Gilman R, Meyer S, Ortega Y, Xiao L. Transmission of Enterocytozoon bieneusi between a child and guinea pigs. *Journal of Clinical Microbiology*. 2007, Aug; 45(8):2708-2710.

BOOK CHAPTERS

1. Meyer S, Cohn A, Orenstein W. “Public Health and Regulatory Issues”. Plotkin’s Vaccines. 8th Edition.
2. Mbaeyi S, Cohn A, Messonnier N. Harrison’s Principles of Internal Medicine. 21st Edition. 2022.
3. Mbaeyi S, Duffy J, McNamara L. Epidemiology and Prevention of Vaccine Preventable Diseases – Meningococcal Disease chapter. 14th Edition. 2021.
4. Mbaeyi S. “Meningococcal Disease”. Maxcy-Rosenau-Last Public Health and Preventive Medicine, 16th edition. 2021. Chapter 104.
5. Mbaeyi S, McNamara L. “Meningococcal Disease. CDC Health Information for International Travel 2020: The Yellow Book. Oxford University Press USA, 2020. Chapter 4.
6. Mbaeyi S, Cohn A, Coldiron M. “Meningococcal Disease. Health in Humanitarian Emergencies: Principles and Practice for Public Health and Healthcare Practitioners. Cambridge University Press, 2018. Chapter 27: 400-406.
7. MacNeil J, Meyer S. “Meningococcal Disease”. CDC Health Information for International Travel 2018: The Yellow Book. Oxford University Press USA, 2018. Chapter 3.
8. MacNeil J, Meyer S. “Meningococcal Disease”. CDC Health Information for International Travel 2015: The Yellow Book. Oxford University Press USA, 2016. Chapter 3: 263-268.